$126.10
3.15% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Ascendis Pharma A/S Sponsored ADR Stock price

$122.25
-18.03 12.85% 1M
-2.74 2.19% 6M
-15.42 11.20% YTD
-20.84 14.56% 1Y
+0.44 0.36% 3Y
-18.31 13.03% 5Y
+103.94 567.67% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-2.84 2.27%
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Key metrics

Market capitalization $7.31b
Enterprise Value $7.49b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 21.13
P/S ratio (TTM) P/S ratio 20.61
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 117.15%
Revenue (TTM) Revenue $354.45m
EBIT (operating result TTM) EBIT $-342.44m
Free Cash Flow (TTM) Free Cash Flow $-277.97m
Cash position $698.11m
EPS (TTM) EPS $-8.10
P/E forward negative
P/S forward 23.25
EV/Sales forward 23.83
Short interest 8.03%
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
94%
Hold
6%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
354 354
117% 117%
100%
- Direct Costs 69 69
46% 46%
19%
285 285
146% 146%
81%
- Selling and Administrative Expenses 269 269
12% 12%
76%
- Research and Development Expense 339 339
26% 26%
96%
-323 -323
45% 45%
-91%
- Depreciation and Amortization 20 20
0% 0%
6%
EBIT (Operating Income) EBIT -342 -342
43% 43%
-97%
Net Profit -462 -462
28% 28%
-130%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Positive
Seeking Alpha
7 days ago
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenue of $62.4M; validates TransCon platform technology. Novo deal for monthly GLP-1 in obesity could be game-changing; includes $285M in milestones plus royalties and expansion options.
Positive
Seeking Alpha
7 days ago
Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth potential. Ascendis' diverse pipeline supports a positive investment thesis, suggesting significant future advancements and market opportunities.
Neutral
GlobeNewsWire
24 days ago
- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P.
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Founded 2006
Website www.ascendispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today